Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 2/2016

11.02.2016

Atypical presentations of thrombotic thrombocytopenic purpura: a diagnostic role for ADAMTS13

verfasst von: Yosef Kalish, Amihai Rottenstreich, Deborah Rund, Sarit Hochberg-Klein

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Thrombotic thrombocytopenic purpura (TTP) is an acute, life threatening disease. Only a minority of patients expresses the complete clinical presentation and unusual manifestations can occur. Demonstration of low activity levels of ADAMTS13 (<5 %) is highly specific for the diagnosis of TTP. This study reports a series of five cases of TTP presenting with a thrombotic event and no hematological findings. Detailed chart reviews on these patients were conducted. We identified two patients whose first attack of TTP presented as a thrombotic episode without microangiopathic hemolytic anemia and thrombocytopenia, only to be diagnosed as TTP days later, after the appearance of hematological signs. We also describe three cases of classical TTP relapsing atypically as cerebrovascular accidents without hematological signs. Low levels of ADAMTS13 activity were detected and facilitated the diagnosis. The neurological manifestations disappeared concurrent with normalization of ADAMTS13 activity level after plasma exchange. This study underscores the importance of having a high clinical suspicion of TTP in cases of thrombosis even without hematological abnormalities in patients with previous attacks of TTP. In this clinical scenario, measurement of ADAMTS13 activity is important for diagnosis and early administration of treatment.
Literatur
1.
Zurück zum Zitat Moschowitz E (1925) An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease. Arch Intern Med (Chic) 36(1):89–93CrossRef Moschowitz E (1925) An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease. Arch Intern Med (Chic) 36(1):89–93CrossRef
2.
Zurück zum Zitat George JN (2010) How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 116:4060–4069CrossRefPubMed George JN (2010) How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 116:4060–4069CrossRefPubMed
3.
Zurück zum Zitat Zhu T, Pan K, Wang Y (2015) Successful resuscitation with thrombolysis of pulmonary embolism due to thrombotic thrombocytopenic purpura during cardiac arrest. Am J Emerg Med 33:132.e3-132.e4CrossRef Zhu T, Pan K, Wang Y (2015) Successful resuscitation with thrombolysis of pulmonary embolism due to thrombotic thrombocytopenic purpura during cardiac arrest. Am J Emerg Med 33:132.e3-132.e4CrossRef
4.
Zurück zum Zitat Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594CrossRefPubMedPubMedCentral Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B (1998) Von willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339(22):1578–1584CrossRefPubMed Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B (1998) Von willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339(22):1578–1584CrossRefPubMed
6.
Zurück zum Zitat Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA, Canadian Apheresis Study Group (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325(6):393–397CrossRefPubMed Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA, Canadian Apheresis Study Group (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325(6):393–397CrossRefPubMed
7.
Zurück zum Zitat Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B, Machin SJ, British Committee for Standards in Haematology (2012) Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 158:323–335CrossRefPubMed Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B, Machin SJ, British Committee for Standards in Haematology (2012) Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 158:323–335CrossRefPubMed
8.
Zurück zum Zitat Tsai HM, Shulman K (2003) Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol 70(3):183–185CrossRefPubMed Tsai HM, Shulman K (2003) Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol 70(3):183–185CrossRefPubMed
9.
Zurück zum Zitat Downes KA, Yomtovian R, Tsai HM, Silver B, Rutherford C, Sarode R (2004) Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident. J Clin Apher 19(2):86–89CrossRefPubMed Downes KA, Yomtovian R, Tsai HM, Silver B, Rutherford C, Sarode R (2004) Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident. J Clin Apher 19(2):86–89CrossRefPubMed
10.
Zurück zum Zitat Just S (2010) Methodologies and clinical utility of ADAMTS-13 activity testing. Semin Thromb Hemost 36:82–90CrossRefPubMed Just S (2010) Methodologies and clinical utility of ADAMTS-13 activity testing. Semin Thromb Hemost 36:82–90CrossRefPubMed
11.
Zurück zum Zitat Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ (2010) ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost 8:631–640CrossRefPubMed Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ (2010) ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost 8:631–640CrossRefPubMed
12.
Zurück zum Zitat O’Brien TE, Crum ED (2002) Atypical presentations of thrombotic thrombocytopenic purpura. Int J Hematol 76(5):471–473CrossRefPubMed O’Brien TE, Crum ED (2002) Atypical presentations of thrombotic thrombocytopenic purpura. Int J Hematol 76(5):471–473CrossRefPubMed
13.
Zurück zum Zitat George JN, Chen Q, Deford CC, Al-Nouri Z (2012) Ten patient stories illustrating the extraordinarily diverse clinical features of patients with thrombotic thrombocytopenic purpura and severe ADAMTS13 deficiency. J Clin Apher 27(6):302–311CrossRefPubMed George JN, Chen Q, Deford CC, Al-Nouri Z (2012) Ten patient stories illustrating the extraordinarily diverse clinical features of patients with thrombotic thrombocytopenic purpura and severe ADAMTS13 deficiency. J Clin Apher 27(6):302–311CrossRefPubMed
14.
Zurück zum Zitat Miura M, Kaikita K, Matsukawa M, Soejima K, Fuchigami S, Miyazaki Y, Ono T, Uemura T, Tsujita K, Hokimoto S, Sumida H, Sugiyama S, Matsui K, Yamabe H, Ogawa H (2010) Prognostic value of plasma von willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease. Thromb Haemost 103(3):623–629CrossRefPubMed Miura M, Kaikita K, Matsukawa M, Soejima K, Fuchigami S, Miyazaki Y, Ono T, Uemura T, Tsujita K, Hokimoto S, Sumida H, Sugiyama S, Matsui K, Yamabe H, Ogawa H (2010) Prognostic value of plasma von willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease. Thromb Haemost 103(3):623–629CrossRefPubMed
15.
Zurück zum Zitat Chauhan AK, Walsh MT, Zhu G, Ginsburg D, Wagner DD, Motto DG (2008) The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Blood 111(7):3452–3457CrossRefPubMedPubMedCentral Chauhan AK, Walsh MT, Zhu G, Ginsburg D, Wagner DD, Motto DG (2008) The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Blood 111(7):3452–3457CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, Zhang W, Tsai HM, Wagner DD, Ginsburg D (2005) Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 115(10):2752–2761CrossRefPubMedPubMedCentral Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, Zhang W, Tsai HM, Wagner DD, Ginsburg D (2005) Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 115(10):2752–2761CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Sarode R, Gottschall JL, Aster RH, McFarland JG (1997) Thrombotic thrombocytopenic purpura: early and late responders. Am J Hematol 54:102–107CrossRefPubMed Sarode R, Gottschall JL, Aster RH, McFarland JG (1997) Thrombotic thrombocytopenic purpura: early and late responders. Am J Hematol 54:102–107CrossRefPubMed
18.
Zurück zum Zitat Sonneveld MA, de Maat MP, Portegies ML, Kavousi M, Hofman A, Turecek PL, Rottensteiner H, Scheiflinger F, Koudstaal PJ, Ikram MA, Leebeek FW (2015) Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood 126:2739–2746CrossRefPubMed Sonneveld MA, de Maat MP, Portegies ML, Kavousi M, Hofman A, Turecek PL, Rottensteiner H, Scheiflinger F, Koudstaal PJ, Ikram MA, Leebeek FW (2015) Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood 126:2739–2746CrossRefPubMed
19.
Zurück zum Zitat Deford CC, Reese JA, Schwartz LH, Perdue JJ, Kremer Hovinga JA, Lammle B, Terrell DR, Vesely SK, George JN (2013) Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood 122:2023–2029CrossRefPubMedPubMedCentral Deford CC, Reese JA, Schwartz LH, Perdue JJ, Kremer Hovinga JA, Lammle B, Terrell DR, Vesely SK, George JN (2013) Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood 122:2023–2029CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Vesely SK (2015) Life after acquired thrombotic thrombocytopenic purpura: morbidity, mortality, and risks during pregnancy. J Thromb Haemost 13(Suppl 1):S216–S222CrossRefPubMed Vesely SK (2015) Life after acquired thrombotic thrombocytopenic purpura: morbidity, mortality, and risks during pregnancy. J Thromb Haemost 13(Suppl 1):S216–S222CrossRefPubMed
21.
Zurück zum Zitat Chaturvedi S, Abbas H, McCrae K (2015) Increased morbidity during long term follow up of survivors of thrombotic thrombocytopenic purpura. Am J Hematol 90:E208CrossRefPubMed Chaturvedi S, Abbas H, McCrae K (2015) Increased morbidity during long term follow up of survivors of thrombotic thrombocytopenic purpura. Am J Hematol 90:E208CrossRefPubMed
Metadaten
Titel
Atypical presentations of thrombotic thrombocytopenic purpura: a diagnostic role for ADAMTS13
verfasst von
Yosef Kalish
Amihai Rottenstreich
Deborah Rund
Sarit Hochberg-Klein
Publikationsdatum
11.02.2016
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 2/2016
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-016-1342-7

Weitere Artikel der Ausgabe 2/2016

Journal of Thrombosis and Thrombolysis 2/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Innere Medizin

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Krebspatienten impfen: Was? Wen? Und wann nicht?

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Nierenultraschall: Tipps vom Profi

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

„KI sieht, was wir nicht sehen“

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.